Perceptions around bone-modifying agent use in patients with bone metastases from breast and castration resistant prostate cancer: a patient survey

BACKGROUND: Optimal use of bone-modifying agent (BMA) therapy in patients with bone metastases from breast and castrate-resistant prostate cancer (CRPC) is evolving. METHODS: Patients receiving BMA for bone metastases from breast or CRPC were surveyed. Information was collected on patient and diseas...

Descripción completa

Detalles Bibliográficos
Autores principales: Alzahrani, Mashari, Clemons, Mark, Sienkiewicz, Marta, Shrem, Noa Shani, McGee, Sharon F., Vandermeer, Lisa, Sehdev, Sandeep, Savard, Marie France, Awan, Arif, Canil, Christina, Hutton, Brian, Pond, Gregory, Saunders, Deanna, Ng, Terry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140584/
https://www.ncbi.nlm.nih.gov/pubmed/34023950
http://dx.doi.org/10.1007/s00520-021-06238-1

Ejemplares similares

Ejemplares similares